Key result
Indomethacin at 0.3 mg/kg daily is linked to higher ductus response rates than graduated dosing.
Why the study?
The therapeutic plasma indomethacin levels for effective ductus closure and associated renal side effects in premature infants with patent ductus arteriosus were not well defined.
Does a higher dose indomethacin regimen improve ductus closure compared to a lower dose regimen in premature infants with patent ductus arteriosus?
Population
Premature infants with patent ductus arteriosus
Comparison
Indomethacin regimen I (0.3 mg/kg q 24 h) vs regimen II (0.1, 0.2, 0.3 mg/kg at 24-hour intervals)
Design
Observational cohort study
Follow-up
72 hours
Authors
Loading...
Higher indomethacin dosing may enhance PDA closure; leaves open optimal regimen and renal safety in preterm infants.
Observational
Does a higher dose indomethacin regimen improve ductus closure compared to a lower dose regimen in premature infants with patent ductus arteriosus?
Higher doses of indomethacin optimize ductus closure in premature infants with PDA without significantly increasing the severity of transient renal adverse effects.
Yeh et al. (2019) conducted an observational in Patent Ductus Arteriosus. Indomethacin Regimen I vs. Indomethacin Regimen II (0.1, 0.2 and 0.3 mg/kg at 24-hour intervals) was evaluated on Ductus response and renal side effects. Indomethacin at 0.3 mg/kg daily yielded higher plasma levels and ductus response rates than a graduated dosing regimen, with a ≥50% closure chance at plasma levels ≥600 ng/ml.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: